Is PDS Biotechnology Corp (PDSB) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 59.3% / 30% | 113.2% / 30% | 0.0% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 59.3% / 33% | 113.2% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 48.1% / 33% | 91.9% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 59.3% / 33% | 113.2% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 48.1% / 33% | 91.9% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -221.8% | |
| Return on Assets (ROA) | -46.2% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$35M |
| Free Cash Flow | -$35M |
| Total Debt | $22M |
| Debt-to-Equity | 190.1 |
| Current Ratio | 2.1 |
| Total Assets | $45M |
Price & Trading
| Last Close | $0.64 |
| 50-Day MA | $0.72 |
| 200-Day MA | $0.99 |
| Avg Volume | 597K |
| Beta | 1.2 |
|
52-Week Range
$0.52
| |
About PDS Biotechnology Corp (PDSB)
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies. The company's lead product candidate is Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein for treating acute myeloid leukemia, prostate, and breast cancer; and PDS0103 for ovarian, breast, colorectal, and lung cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate, tumor-targeting interleukin 12 immune-cytokine that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment. Further, the company provides PDS0202, a novel investigational influenza vaccine that protects against the strains predicted to be prevalent in an upcoming flu season. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Princeton, New Jersey.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is PDS Biotechnology Corp (PDSB) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), PDS Biotechnology Corp is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is PDS Biotechnology Corp's debt ratio?
PDS Biotechnology Corp's debt ratio is 59.3% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 48.1%.
What are PDS Biotechnology Corp's key financial metrics?
PDS Biotechnology Corp has a market capitalization of $30M. Return on equity stands at -221.8%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.